已收盤 11-20 16:00:00 美东时间
-0.051
-4.82%
11月21日,Gain Therapeutics(GANX)收跌4.82%,报1美元,成交额60.4万美元,市值4449.86万美元。 行情数据 • 开盘价:...
11-21 08:25
Gain Therapeutics announced positive clinical data from a Phase 1b study of rexaceract for Parkinson's disease, showing stable MDS-UPDRS motor scores and no disease progression in 13 participants after 12 months of treatment. The study also highlighted the potential of cerebrospinal fluid (CSF) GluSph as a disease-specific biomarker, with differential responses observed between Parkinson's patients and one participant diagnosed with multiple syst...
11-17 21:15
11月13日,Gain Therapeutics(GANX)收跌2.7%,报1.08美元,成交额32.61万美元,市值4808.72万美元。 行情数据 • 开盘...
11-13 09:10
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.12) by 41.67 percent. This is a 53.33 percent increase over losses of $(0.15) per share from the same period last year.
11-10 20:18
11月6日,Gain Therapeutics(GANX)收跌13.48%,报0.96美元,成交额84.33万美元,市值4191.53万美元。 行情数据 • 开...
11-06 08:29
Gain Therapeutics announced the presentation of two late-breaking posters at the 31st IAPRD World Congress on Parkinson’s Disease in Milan and one poster at Neuroscience 2026 in Washington, D.C. The posters highlight the company’s lead drug candidate, rexaceract (GT-02287), and its novel GCase allosteric modulator GT-04686, focusing on their potential in treating Parkinson’s disease and related disorders. The posters will be presented during guid...
11-05 12:00
11月3日,Gain Therapeutics(GANX)收平,报1.13美元,成交额31.19万美元,市值4931.73万美元。 行情数据 • 开盘价:1....
11-03 08:22
10月27日,Gain Therapeutics(GANX)收跌8.73%,报1.15美元,成交额96.95万美元,市值5019.02万美元。 行情数据 • 开...
10-27 07:24
10月20-22日上海黄浦江畔,2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势,更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:25
Gain Therapeutics, Inc. will participate in the 2026 Maxim Growth Summit from October 12-14 in New York City. The company will meet with institutional investors and engage with Maxim research analysts. Gain’s lead drug candidate, rexaceract, is in a Phase 1b trial for Parkinson’s disease and has potential for Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. The company uses its Magellan™ platform to develop novel allosteric ...
10-08 11:00